The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Using retrospective analysis, researchers sought to identify biomarkers to predict the effectiveness of isatuximab, an anti-CD38 antibody widely used in treatments for patients with relapsed/refractory multiple myeloma, by focusing on the host's immune status before treatment. It was found that the patients with higher lymphocyte/monocyte ratio (≥ 4) could obtain longer progression-free survival and overall survival under the isatuximab and/or dexamethasone (Isa-D) regimen over other regimens.